Morton Zoey, Green Danetta, Grisham Matt
University of South Carolina School of Medicine Greenville, SC, USA.
Department of Pediatrics, Prisma Health, University of South Carolina School of Medicine Greenville, SC, USA.
Arch Clin Cases. 2022 Apr 6;9(1):1-5. doi: 10.22551/2022.34.0901.10195. eCollection 2022.
Numerous vaccines have been developed to address the COVID-19 pandemic, the most frequently administered are the Moderna and Pfizer-BioNTech (Pfizer) mRNA COVID-19 vaccines. Of 177 million individuals that have full vaccination status, there have been 1,148 cases of myocarditis or pericarditis reported. At this time, the relationship between myopericarditis and the Pfizer mRNA COVID-19 vaccine has not been well established in current literature due to the novelty of the vaccine. We discuss a 16-year-old male who presented to the emergency department with chest pain 48 hours after receiving his second dose of the Pfizer COVID-19 vaccine. His laboratory and electrocardiogram findings were consistent with acute myopericarditis and work-up did not reveal an obvious etiology. After starting anti-inflammatory therapies, the patient's symptoms and laboratory markers improved and the patient was discharged from the hospital expected to make a full recovery. This case demonstrates the rapid recovery with no sequelae following this adverse effect, highlighting that the benefits of the COVID-19 vaccination most likely outweigh the risks.
为应对新冠疫情已研发出多种疫苗，其中使用最为频繁的是莫德纳和辉瑞-生物科技公司（辉瑞）的新冠信使核糖核酸疫苗。在1.77亿已完成全程接种的人群中，共报告了1148例心肌炎或心包炎病例。目前，由于该疫苗尚属新型，现有文献中关于心肌心包炎与辉瑞信使核糖核酸新冠疫苗之间的关系尚未明确。我们讨论一名16岁男性，在接种第二剂辉瑞新冠疫苗48小时后因胸痛前往急诊科就诊。其实验室检查和心电图结果符合急性心肌心包炎表现，进一步检查未发现明显病因。在开始抗炎治疗后，患者症状和实验室指标改善，出院时预计可完全康复。该病例显示出这种不良反应后恢复迅速且无后遗症，凸显了新冠疫苗接种的益处很可能大于风险。
